1.2326

2.40% -0.0174

Telomir Pharmaceuticals Inc (TELO)

Overview News Price History Discussions Forecast

Telomir Pharmaceuticals Inc stock is traded at $1.2326, with a volume of 15,245. It is down -2.40% in the last 24 hours and up +7.96% over the past month. Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.

Previous Close:

$1.25

Open:

$1.24

24h Volume:

15,245

Relative Volume:

0.20

Market Cap:

$83.91M

Revenue:

Net Income/Loss:

$-9.22M

P/E Ratio:

-4.2256

EPS:

-0.2917

Net Cash Flow:

$-4.60M

1W Performance:

+7.96%

1M Performance:

+7.96%

6M Performance:

-4.69%

1Y Performance:

-19.74%

1-Day Range:

$1.21

$1.245

1-Week Range:

$1.10

$1.30

52-Week Range:

$0.8885

$2.091

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Name

Telomir Pharmaceuticals Inc

Sector

Healthcare (1072)

Industry

Biotechnology (597)

Phone

786-396-6723

Address

100 SE 2ND ST, MIAMI

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

TELO's Discussions on Twitter

Compare TELO vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TELO Telomir Pharmaceuticals Inc	1.22	85.97M	0	-9.22M	-4.60M	-0.2917
VRTX Vertex Pharmaceuticals Inc	513.45	130.53B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	795.60	82.77B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	184.69	72.88B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	950.54	60.30B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	362.94	41.64B	5.76B	514.49M	1.10B	4.4813

Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-25	Initiated	Rodman & Renshaw	Buy

Telomir Pharmaceuticals Inc Stock (TELO) Latest News

Sep 22, 2026

Experimental drug found to slow bone cancer cell growth in dog and human lab tests - DVM360

Sep 22, 2026

Sep 17, 2026

Telomir announces preclinical study on AMD treatment candidate - Investing.com

Sep 17, 2026

Telomir announces preclinical study on AMD treatment candidate By Investing.com - Investing.com Nigeria

Sep 17, 2026

Telomir-Zn Preclinical Data Highlight Retinal Regeneration Potential - TipRanks

Sep 17, 2026

Vision gains in fish study link Telomir (NASDAQ: TELO) eye data to its cancer program - Stock Titan

Sep 17, 2026

Maxim Group Initiates Telomir Pharmaceuticals(TELO.US) With Buy Rating, Announces Target Price $4 - Moomoo

Sep 17, 2026

An experimental drug improved vision in an AMD model. Telomir’s focus is cancer. - Stock Titan

Sep 17, 2026

Sep 16, 2026

Telomir (TELO) investors approve all 2026 votes - Stock Titan

Sep 16, 2026

Sep 14, 2026

Form 8K Telomir Pharmaceuticals Inc For: 14 September By Investing.com - Investing.com Nigeria

Sep 14, 2026

Telomir unveils new preclinical data for Telomir-Zn - TipRanks

Sep 14, 2026

Telomir Pharmaceuticals Announces Research Demonstrating In-Vitro Anti-Cancer Activity Of Telomir-Zn In Human And Canine Osteosarcoma Models - marketscreener.com

Sep 14, 2026

Telomir Announces Research with The Ohio State University - GlobeNewswire

Sep 14, 2026

Sep 04, 2026